Cargando…

Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019

IMPORTANCE: Government and the pharmaceutical industry make substantive contributions to pharmaceutical innovation. This study compared the investments by the National Institutes of Health (NIH) and industry and estimated the cost basis for assessing the balance of social and private returns. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galkina Cleary, Ekaterina, Jackson, Matthew J., Zhou, Edward W., Ledley, Fred D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148199/ https://www.ncbi.nlm.nih.gov/pubmed/37115539 http://dx.doi.org/10.1001/jamahealthforum.2023.0511

Ejemplares similares

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
por: Zhou, Edward W., et al.
Publicado: (2023)

NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole
por: Ledley, Fred D., et al.
Publicado: (2023)

Contribution of NIH funding to new drug approvals 2010–2016
por: Galkina Cleary, Ekaterina, et al.
Publicado: (2018)

NIH funding for vaccine readiness before the COVID-19 pandemic
por: Kiszewski, Anthony E., et al.
Publicado: (2021)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2020)

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020)

Comparing long-term value creation after biotech and non-biotech IPOs, 1997–2016
por: Cleary, Ekaterina Galkina, et al.
Publicado: (2021)

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries
por: Chow, Ryan D., et al.
Publicado: (2022)

Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare: A Difference-in-Differences Analysis
por: Schwartz, Aaron L., et al.
Publicado: (2021)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

Plan Selection, Enrollee Risk, and Health Spending on the Patient Protection and Affordable Care Act Individual Marketplaces, 2019
por: Treasure, Graham, et al.
Publicado: (2023)

Hospital Characteristics Associated With Heterogeneity in Institutional Postacute Care Spending Reductions Under the Comprehensive Care for Joint Replacement Model
por: Meath, Thomas H. A., et al.
Publicado: (2022)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2022)

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023)

Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps
por: Dusetzina, Stacie B., et al.
Publicado: (2021)

Determinants of Growth in Prescription Drug Spending Using 2010–2019 Health Insurance Claims Data
por: Lee, HyeYeong, et al.
Publicado: (2021)

Ethnic-Regional Differences in the Allocation of High Complexity Spending in Brazil: Time Analysis 2010–2019
por: Martins, Luiz Oscar Machado, et al.
Publicado: (2023)

Assessment of Spending for Patients Initiating Dialysis Care
por: League, Riley J., et al.
Publicado: (2022)

Spending on and Use of Clinician-Administered Drugs in Medicare
por: Hyland, Megan F., et al.
Publicado: (2023)

Comparison of Postpartum Health Care Use and Spending Among Individuals with Medicaid-Paid Births Enrolled in Continuous Medicaid vs Commercial Insurance
por: Gordon, Sarah H., et al.
Publicado: (2022)

Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
por: Ozieranski, Piotr, et al.
Publicado: (2019)

Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019
por: Ballreich, Jeromie M., et al.
Publicado: (2021)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Comparison of Use of Health Care Services and Spending for Unauthorized Immigrants vs Authorized Immigrants or US Citizens Using a Machine Learning Model
por: Wilson, Fernando A., et al.
Publicado: (2020)

Downstream Mammary and Extramammary Cascade Services and Spending Following Screening Breast Magnetic Resonance Imaging vs Mammography Among Commercially Insured Women
por: Ganguli, Ishani, et al.
Publicado: (2022)

Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms
por: Shah, Prateet, et al.
Publicado: (2023)

Association of Medicare Spending With Subspecialty Consultation for Elderly Hospitalized Adults
por: Ryskina, Kira L., et al.
Publicado: (2019)

Association of Chain Restaurant Advertising Spending With Obesity in US Adults
por: Bleich, Sara N., et al.
Publicado: (2020)

Association of State Medicaid Expansion With Hospital Community Benefit Spending
por: Kanter, Genevieve P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cnv5g44cmis2qgnbak8sadlojm